A Tale of Two Giants: SG&A Expenses of Johnson & Johnson vs. Galapagos NV

In the world of pharmaceuticals, understanding the financial dynamics of industry leaders is crucial. Johnson & Johnson, a titan in healthcare, and Galapagos NV, a rising biotech star, offer a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses over the past decade.

From 2014 to 2023, Johnson & Johnson consistently reported SG&A expenses exceeding $20 billion annually, reflecting its expansive global operations. In contrast, Galapagos NV's expenses, while growing, remained under $250 million, highlighting its focused, innovative approach.

Interestingly, Galapagos NV saw a significant increase in SG&A expenses, peaking in 2022 with a 2,500% rise from 2014. Meanwhile, Johnson & Johnson's expenses showed a slight decline, dropping by approximately 13% from their 2014 peak.

This financial snapshot underscores the diverse strategies of these companies, with Johnson & Johnson leveraging scale and Galapagos NV emphasizing agility and innovation.